EP 4028037 A4 20230628 - METHODS OF TREATING OCULAR NEOVASCULAR DISEASES USING AAV2 VARIANTS ENCODING AFLIBERCEPT
Title (en)
METHODS OF TREATING OCULAR NEOVASCULAR DISEASES USING AAV2 VARIANTS ENCODING AFLIBERCEPT
Title (de)
VERFAHREN ZUR BEHANDLUNG VON NEOVASKULÄREN ERKRANKUNGEN UNTER VERWENDUNG VON AAV2-VARIANTEN, DIE FÜR AFLIBERCEPT KODIEREN
Title (fr)
MÉTHODES DE TRAITEMENT DE MALADIES NÉOVASCULAIRES OCULAIRES À L'AIDE DE VARIANTS D'AAV2 CODANT POUR L'AFLIBERCEPT
Publication
Application
Priority
- US 201962913648 P 20191010
- US 201962899070 P 20190911
- US 2019062066 W 20191118
Abstract (en)
[origin: CA3147843A1] Provided are methods for treating an ocular neovascular disease in an individual, comprising administering a unit dose of recombinant adeno-associated virus (rAAV) particles to an eye of the individual, wherein the rAAV particles comprise: a) a nucleic acid encoding a polypeptide comprising an amino acid sequence with at least about 95% identity to the amino acid sequence of SEQ ID NO: 35 and flanked by AAV2 inverted terminal repeats (ITRs), and b) an AAV2 capsid protein comprising an amino acid sequence LGETTRP (SEQ ID NO. 14) inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to an AAV2 VP1 capsid protein
IPC 8 full level
A61K 31/00 (2006.01); A61K 35/761 (2015.01); A61K 38/17 (2006.01); A61P 27/02 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01)
CPC (source: EP IL KR)
A61K 9/0048 (2013.01 - KR); A61K 31/575 (2013.01 - KR); A61K 38/179 (2013.01 - EP IL KR); A61K 45/06 (2013.01 - KR); A61K 47/02 (2013.01 - KR); A61K 47/10 (2013.01 - KR); A61K 48/005 (2013.01 - IL); A61K 48/0075 (2013.01 - IL); A61P 27/02 (2017.12 - EP IL KR); C07K 16/00 (2013.01 - EP IL); C12N 15/86 (2013.01 - IL); A61K 48/005 (2013.01 - EP KR); A61K 48/0075 (2013.01 - EP KR); C07K 14/71 (2013.01 - KR); C07K 2319/30 (2013.01 - EP IL); C07K 2319/32 (2013.01 - EP IL); C12N 15/86 (2013.01 - EP KR); C12N 2710/14144 (2013.01 - EP IL KR); C12N 2750/14143 (2013.01 - EP IL KR)
Citation (search report)
- [XI] WO 2017218974 A2 20171221 - ADVERUM BIOTECHNOLOGIES INC [US]
- [A] WO 2018170473 A1 20180920 - ADVERUM BIOTECHNOLOGIES INC [US]
- [I] RUSLAN GRISHANIN ET AL: "Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration", MOLECULAR THERAPY, vol. 27, no. 1, 1 January 2019 (2019-01-01), US, pages 118 - 129, XP055643284, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2018.11.003
- [A] RAKOCZY ELIZABETH P ET AL: "Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial", THE LANCET, ELSEVIER, AMSTERDAM, NL, vol. 386, no. 10011, 30 September 2015 (2015-09-30), pages 2395 - 2403, XP029344231, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(15)00345-1
- [A] MARTINA SANTARELLI ET AL: "Advances in pharmacotherapy for wet age-related macular degeneration", EXPERT OPINION, vol. 16, no. 12, 13 July 2015 (2015-07-13), pages 1769 - 1781, XP055331172, DOI: 10.1517/14656566.2015.1067679
- [A] KEVIN ISGRIG ET AL: "AAV2.7m8 is a powerful viral vector for inner ear gene therapy", NATURE COMMUNICATIONS, vol. 10, no. 1, 25 January 2019 (2019-01-25), XP055675029, DOI: 10.1038/s41467-018-08243-1
- See references of WO 2021050094A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
AU 2019465527 A1 20220310; BR 112022003206 A2 20220816; CA 3147843 A1 20210318; CN 114390928 A 20220422; EP 4028037 A1 20220720; EP 4028037 A4 20230628; IL 291226 A 20220501; JP 2023509263 A 20230308; KR 20220062352 A 20220516; MX 2022002960 A 20220406
DOCDB simple family (application)
AU 2019465527 A 20191118; BR 112022003206 A 20191118; CA 3147843 A 20191118; CN 201980100210 A 20191118; EP 19944875 A 20191118; IL 29122622 A 20220309; JP 2022515693 A 20191118; KR 20227011743 A 20191118; MX 2022002960 A 20191118